1615

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-003

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/511,463 Filing Date TRANSMITTAL October 14, 2004 **FORM** First Named Inventor Yuval Simha Landschaft **Art Unit Examiner Name** correspondence after initial filing) Attorney Docket Number RO0908US (#90568) of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a **Proprietary Information** After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): return postcard receipt and prior art Request for Refund **Express Abandonment Request** references CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name D. Peter Hochberg Co., L.P.A. Signature Printed name D. Peter Hochberg Date Reg. No. 24,603 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Sean Mellino 03/16/2005 Typed or printed name

4-

\$

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope deletersed: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date noted below:

Date: March 16, 2005

Sean Mellino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :

Yuval Simha Landschaft

Serial No.

MAR 2 1 2005

10/511,463 (Conf. No. 9282)

Filing Date

October 14, 2004

Examiner

er :

Group Art Unit:

Title

A PLATFORM FOR TRANSDERMAL

FORMULATIONS (PTF)

Attorney File:

RO0908US (#90568)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to submit copies of the non-patent, literature references listed on the attached Form PTO-1449, each of which was listed in the Information Disclosure Statement filed with the application on October 14, 2004.

Applicant would also like to call the Examiner's attention to the additional non-patent, literature reference (the second reference for Shichiri, et al.) listed on the attached Form PTO-1449, a copy of which is also enclosed.

In accordance with 37 C.R.F. 1.97(b)(3), and as this Information Disclosure Statement is

2

being filed before the issuance of a first Official action on the merits of the application, no government fee or statement under 37 C.F.R. 1.97(e) is required.

In accordance with 37 C.F.R. 1.97(g) and 37C.F.R.1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.

Respectfully submitted,

D. Peter Hochberg

Reg. No. 24,603

D. Peter Hochberg Co., L.P.A. 1940 E.6th Street – 6th Floor Cleveland, OH 44114-2294 (216) 771-3800 DPH/sfm

FORM PTO-1449

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	OIPE	Yuval Simha Landschaft
Serial No.	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	10/511,463 (Conf. No. 9282)
Filing Date	MAR 2 1 2005	October 14, 2004
Examiner	TRANSMARK!	,

Group Art Unit:

Title :

A PLATFORM FOR TRANSDERMAL

FORMULATIONS (PTF)

Attorney File:

RO0908US (#90568)

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

Other Prior Art (Inc. Author, Title, Date, Pertinent Pages, Etc)

Examiner	
Initial	Document
	Chang, S.L., et al., Intern. J. Pharmac., 200:107-113 (2000)
	Foldvari, M., Biotechnol. Appl. Biochem., 30:129-137 (1999)
	Geisser, P., et al., Arzneimittelforschung, 41(1): 32-37 (1991)
	Guo, J., et al., <u>Drug Deliv.</u> , 7(2): 113-116 (2000)
	Kleinbloesem, C.H., et al., <u>Arzneimittelforschung</u> , 45 (10): 1117-1121 (1995)
	Rehman, Q., et al., Osteoporos Int., 14: 77-81 (2003)

	Shichiri, M., et al., <u>in Diabetologia</u> , 10: 317-321 (1974)
	Shichiri, M., et al., <u>Diabetes</u> , Vol. 24, No., 11: 971-976 (Nov., 1975)
	Suzuki, Y., et al., <u>J. Pharm. Pharmacol.</u> , 53:1227-1234 (2001)
	Tachibana, K., et al., <u>J. Pharm. Pharmacol.</u> , 43(4): 270-271 (1991)
	Thorand, B., et al., Southeast Asian J. Trop. Med. Public Health, 24 (4): 624-630 (1993)
	Verhoef, J.C., Eur. J. Durg Metab. Pharmacokinet., 15(2): 83-93 (1990)
Examiner	Date Considered:
Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant

*** Denotes that copies will follow